Purging disorder

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Retrieved on: 
星期四, 二月 2, 2023
Safety, United Kingdom, Pain, Cancer, Patient, Purging disorder, Clinical trial, M.D, Pharmaceutical industry

The first stage of the CAReS clinical trial is intended to evaluate the safety of ART27.13.

Key Points: 
  • The first stage of the CAReS clinical trial is intended to evaluate the safety of ART27.13.
  • Following a review of initial treatment data from the Phase 1b, Artelo expects to select the optimal dose for the randomized Phase 2a stage of CAReS, which is designed to further explore safety and efficacy of ART27.13.
  • “Participants in the fourth and final cohort in the Phase 1b stage of CAReS are being treated at the highest dose allowed by the protocol, 650 micrograms,” said Steven D. Reich, M.D, Chief Medical Officer of Artelo Biosciences.
  • We are highly encouraged by the safety profile thus far, and eagerly await the results of this important study.

Clementine Palmetto Bay Now Open to Treat Adolescent Girls with Eating Disorders

Retrieved on: 
星期四, 一月 19, 2023
Purging disorder, Binge eating disorder, McLean, Eating disorder, Psychiatry, LMHC, Adolescence, Clementine, Anorexia nervosa, Mortality, Exercise addiction, Doctor of Philosophy, Casino, Health insurance, Medicine

MIAMI, Jan. 19, 2023 /PRNewswire/ -- Monte Nido & Affiliates, one of the largest and leading eating disorder platforms in the country, today announces the opening of Clementine Palmetto Bay located in Palmetto Bay, Fla. This residential eating disorder center will provide care for adolescent girls with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction. Clementine Palmetto Bay is Monte Nido & Affiliates' second Clementine program in the state of Florida.

Key Points: 
  • MIAMI, Jan. 19, 2023 /PRNewswire/ -- Monte Nido & Affiliates , one of the largest and leading eating disorder platforms in the country, today announces the opening of Clementine Palmetto Bay located in Palmetto Bay, Fla.
  • This residential eating disorder center will provide care for adolescent girls with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction.
  • Clementine Palmetto Bay is Monte Nido & Affiliates' second Clementine program in the state of Florida.
  • Clementine Palmetto Bay will be the fourth Monte Nido & Affiliates program in Florida and will complement its nearby program Clementine Pinecrest for adolescent females in Miami.

Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ Patients

Retrieved on: 
星期二, 十二月 13, 2022
Biotechnology, FDA, Health, Family, Consumer, Other Health, Pharmaceutical, Oncology, Other Science, Research, Managed Care, Genetics, Science, Women, Recurrence, Liver, Hepatotoxicity, Cancer, Uric acid, Mucositis, Disease, Woman, AML, URAC, Hypertension, Potassium, Transaminase, Rash, Sodium, Azacitidine, Partnership, Degenerative disease, Knowledge, HUB, ACHC, Fatigue, Hypotension, Alkaline phosphatase, Clinical trial, Constipation, Fatality, Leukocytosis, Probability, Retinoic acid syndrome, Creatinine, AST, Diarrhea, Jaundice, Postcholecystectomy syndrome, Weight gain, Market access, Dexamethasone, Purging disorder, Edema, Case management (US healthcare system), Mutation, Acute kidney injury, Lymphocyte, Lipase, Disorder, IDH1, CYP3A, Patient, Myelocyte, Nausea, FDA, Hydroxycarbamide, ALT, Breathe Me, Arthralgia, Bilirubin, Accreditation Commission for Health Care, Acute myeloid leukemia, Pharmaceutical industry, Generic drug, Rigel, Fever

Scott Yohe, Vice President Market Access at Rigel Pharmaceuticals, says, We are excited to work with Optime Care in the complete management of our Rezlidhia patients.

Key Points: 
  • Scott Yohe, Vice President Market Access at Rigel Pharmaceuticals, says, We are excited to work with Optime Care in the complete management of our Rezlidhia patients.
  • If differentiation syndrome is suspected, withhold REZLIDHIA and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution.
  • Of the 25 patients who experienced differentiation syndrome, 19 (76%) recovered after treatment or after dose interruption of REZLIDHIA.
  • Our experience with small patient populations, coupled with our strategic partnership with AscellaHealth , enhances our services and ability to serve the specialty pharmacy market.

Elanco Announces FDA Approval of Bexacat™ (bexagliflozin tablets) – the First-of-its-Kind Oral Feline Diabetes Treatment Option

Retrieved on: 
星期五, 十二月 9, 2022
Veterinary, FDA, Pets, Other Natural Resources, Health, Consumer, Pharmaceutical, Agriculture, Natural Resources, PETS, Elanco, Cat, Insulin, Veterinarian, Diabetes, ELAN, Coma, Weakness, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Needle, Research, Clinical Science (journal), Diarrhea, Prevalence, Animal, Purdue University, Dehydration, College, Death, NYSE, Family, Liver, Disease, FDA, Vomiting, Professor, Weight loss, Human, Type 1 diabetes, Ohio State University, Diabetic ketoacidosis, Purging disorder, SGLT2, Lethargy, Veterinary medicine, Health, Depression, Farmer, Risk, Pharmaceutical industry, Birth control, Food

Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA in any animal species.

Key Points: 
  • Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA in any animal species.
  • Bexacat introduces a new mechanism of action for veterinarians and pet owners that offers a non-insulin, needle-free, once-daily oral medication specifically designed for cats with diabetes mellitus.
  • This first-in-class therapeutic is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
  • Bexacat integrates seamlessly into the busy lifestyle of pet owners and provides a needle-free approach to managing diabetes in cats.

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

Retrieved on: 
星期四, 十二月 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, QT, Hypersensitivity, ESR1, Hypocalcemia, Peripheral neuropathy, Anemia, Angioedema, Headache, AstraZeneca, Syncope, Woman, Duane syndrome, Hives, Xeroderma, Paced Auditory Serial Addition Test, Leukopenia, Sciatic nerve, Risk, Indigestion, Thrombocytopenia, Lung, Rash, Myalgia, Liver, Fatigue, Pain, Back pain, US Foods, Photopsia, Birth, Immunoassay, Constipation, Hair, Infant, Infection, Food, Neutropenia, Bleeding, Bradycardia, Pregnancy, Dysgeusia, Cough, Diarrhea, Estradiol, Itch, PFS, Tears, Neuralgia, CI, Purging disorder, Grade, Mutation, Xerostomia, Vertigo, Patient, Fulvestrant, Nausea, Vomiting, Incidence, Aromatase, Breathe Me, Arthralgia, Erythema, Bone pain, Stomatitis, Weakness, Sciatica, Fetus, Neuropathic pain, Appetite, Pharmaceutical industry, Vaccine, Dietary supplement, Fever

AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.

Key Points: 
  • AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.
  • Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the last dose.
  • SERENA-2 is a randomized, open-label, parallel group, multicenter Phase II trial evaluating camizestrant at several dose levels compared to FASLODEX in advanced ER-positive, HER2-negative breast cancer.
  • The primary endpoints are PFS defined by response evaluation criteria in solid tumors (RECIST) version 1.1 for 75mg camizestrant versus FASLODEX and for 150mg camizestrant versus FASLODEX.

Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer

Retrieved on: 
星期四, 十二月 8, 2022
Oncology, Health, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, QT, Indigestion, Thrombocytopenia, ORR, Hypersensitivity, Neutropenia, Rash, Bleeding, Xerostomia, Pregnancy, Dysgeusia, Cough, Hypocalcemia, Vertigo, Patient, Diarrhea, Peripheral neuropathy, Estradiol, OS, Myalgia, Anemia, Liver, Angioedema, Itch, Nausea, Fulvestrant, Neuralgia, Headache, Tears, Fatigue, Vomiting, Syncope, Pain, Back pain, Appetite, Breathe Me, Woman, Incidence, Arthralgia, Erythema, Bone pain, Birth, Stomatitis, Duane syndrome, Hives, Immunoassay, Constipation, Safety, Purging disorder, Hair, Xeroderma, Infant, Sciatica, Weakness, Paced Auditory Serial Addition Test, Infection, Fetus, Leukopenia, AES, Neuropathic pain, Sciatic nerve, Risk, Medical imaging, Vaccine, Dietary supplement, Fever

CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.

Key Points: 
  • CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.
  • Capivasertib is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for hematologic malignancies.
  • Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION).
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

SunCloud Health Expands Access to Treatment for Complex Mental Health Conditions, Eating Disorders and Addiction in the Chicago Area

PHP, Lincoln Park, Transcranial magnetic stimulation, Disease management, MD, Head, IOP, Addiction, Patient, TMS, Research, OCD, PTSD, FDA, Eating, Purging disorder, Binge eating disorder, Health, Mental health, Ketamine, Quality of life, History, TRD, Brain, Esketamine, Anxiety, Depression, Residential care, Medicine, Dentistry, Pharmaceutical industry

NORTHBROOK, Ill., Dec. 8, 2022 /PRNewswire/ -- SunCloud Health, a premier provider of residential and outpatient care for complex mental health, eating disorders and substance use disorders, is expanding its services to meet the growing need for mental health care in Chicagoland and nationally.

Key Points: 
  • NORTHBROOK, Ill., Dec. 8, 2022 /PRNewswire/ -- SunCloud Health,a premier provider ofresidential and outpatient carefor complex mental health, eating disordersand substance usedisorders,is expandingits servicestomeet the growing needfor mental health carein Chicagoland and nationally.
  • In January, SunCloud Health will open a new, 20-bed residential treatment center, The Institute for Co-occurring Eating Disorders and Addiction at SunCloud Health, that specializes in treating adults with co-occurring eating disorders and substance use disorders.
  • "Too often, patients withaco-occurring eating disorder and addiction are left to choose between getting either intensive eating disorder treatment or intensive addiction treatment,"Dennissays.
  • SunCloud Health is an integrated, intensive outpatient, partialhospitalization,and residential treatment center with locations in Northbrook, Naperville and Chicago (Lincoln Park).

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Retrieved on: 
星期三, 十二月 7, 2022
CLL, Heart, Food, Rash, Teva, Cough, NHL, Patient, Diarrhea, Chronic lymphocytic leukemia, Research, Food and Drug Administration, Nausea, Aplastic anemia, Headache, United States National Library of Medicine, Fatigue, FDA, Vomiting, Injection, Breathe Me, US Foods, MedlinePlus, Pharmacist, Anaphylaxis, Growth, Constipation, AP, Safety, Purging disorder, Accord, National library, Infection, Tumor lysis syndrome, Rituximab, Intas Biopharmaceuticals, MEDLINE, Pharmaceutical industry, Fever, Bendamustine

DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Bendamustine Lyo. Injection to its line of chemotherapy drugs. Accord's product is AP rated to Teva's Treanda® and is being offered in both 25-mg and 100-mg vials.

Key Points: 
  • DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Bendamustine Lyo.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.
  • Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do.

Walden Behavioral Care Opens First-of-Its-Kind Clinic in Middletown

Retrieved on: 
星期四, 十一月 17, 2022
Purging disorder, Hospital, LICSW, Adolescence, COVID-19, ARFID, Insurance, MBA, Eating disorder, Patient, National Eating Disorders Association, Binge eating disorder, MSW, Walden, Medicine, Pharmaceutical industry

MIDDLETOWN, Conn., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Walden Behavioral Care , a leading specialty healthcare system focused on the treatment of eating disorders, announced today the opening of a new ambulatory clinic located at 214 Court St., in Middletown.

Key Points: 
  • MIDDLETOWN, Conn., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Walden Behavioral Care , a leading specialty healthcare system focused on the treatment of eating disorders, announced today the opening of a new ambulatory clinic located at 214 Court St., in Middletown.
  • The clinic is the first of its kind in Middletown and offers dedicated eating disorder treatment to individuals of all genders 12 years and older.
  • Our new Middletown ambulatory clinic demonstrates Waldens commitment to providing community-based care to all who need it, said Vass.
  • Walden Behavioral Care, an affiliate program of Monte Nido & Affiliates, offers specialized eating disorder support at all levels of care for individuals of all genders.

Monte Nido & Affiliates to Expand Access to Adolescent Eating Disorder Treatment in Florida with New Palmetto Bay Location

Retrieved on: 
星期二, 十一月 15, 2022
Doctor of Philosophy, Eating disorder, Exercise addiction, Mortality, MD, Adolescence, Clementine, Anorexia nervosa, Research, Program, Joint Commission, Binge eating disorder, Rosewood Center, LMHC, Purging disorder, Health insurance, Medicine, Network affiliate

MIAMI, Nov. 15, 2022 /PRNewswire/ -- Monte Nido & Affiliates, one of the largest and leading eating disorder platforms in the country, announces the upcoming opening of a new residential eating disorder center just south of Miami, FL, in Palmetto Bay. Opening early 2023, Clementine Palmetto Bay will provide care for adolescent girls with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction, making it the second Clementine residential treatment program in Florida.

Key Points: 
  • "Eating disorders are devastating from both a psychological and medical perspective," said Joel Jahraus, MD, FAED, CEDS, Chief Medical Officer of Monte Nido & Affiliates.
  • Clementine Palmetto Bay will be the fourth Monte Nido & Affiliates program in Florida and will complement its nearby program Clementine Pinecrest for adolescent females in Miami.
  • Monte Nido & Affiliates is one of the country's largest and leading eating disorder platforms, offering inpatient, residential, and day treatment programs for eating disorders.
  • Monte Nido & Affiliates includes five distinct eating disorder program brands: Monte Nido, Walden Behavioral Care, Rosewood Centers, Oliver-Pyatt Centers, and Clementine.